Aktis Oncology, Inc. (AKTS)Healthcare | Biotechnology | Boston, United States | NasdaqGS
20.25 USD
+1.65
(8.871%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 20.30 +0.05 (0.247%) ⇧ (April 17, 2026, 7:52 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 8:15 p.m. EDT
AKTS is currently a short-term momentum play fueled by strong post-IPO technicals, insider buying, and a breakout above key moving averages, but it remains a long-term speculative risk due to negative earnings, a negative book value, and the absence of any dividend yield. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 6.167 |
| Revenue per Share | 7.986 |
| Market Cap | 1,119,339,008 |
| Forward P/E | -12.17 |
| Website | https://www.aktisoncology.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.095982134 |
| Address1 | 17 Drydock Avenue |
| Address2 | Suite 17-401 |
| All Time High | 29.16 |
| All Time Low | 14.72 |
| Ask | 20.53 |
| Ask Size | 3 |
| Average Daily Volume10 Day | 262,690 |
| Average Daily Volume3 Month | 350,943 |
| Average Volume | 350,943 |
| Average Volume10Days | 262,690 |
| Bid | 19.56 |
| Bid Size | 3 |
| Book Value | -159.68 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.25 |
| Current Ratio | 7.373 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 20.4 |
| Day Low | 18.795 |
| Debt To Equity | 6.167 |
| Display Name | Aktis Oncology |
| Earnings Timestamp End | 1,778,270,400 |
| Earnings Timestamp Start | 1,778,270,400 |
| Ebitda | -72,355,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -17.103 |
| Enterprise To Revenue | 190.474 |
| Enterprise Value | 1,237,508,992 |
| Eps Current Year | -1.23333 |
| Eps Forward | -1.66333 |
| Eps Trailing Twelve Months | -1.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.4526 |
| Fifty Day Average Change | 1.7973995 |
| Fifty Day Average Change Percent | 0.0974063 |
| Fifty Two Week Change Percent | -9.598213 |
| Fifty Two Week High | 29.16 |
| Fifty Two Week High Change | -8.91 |
| Fifty Two Week High Change Percent | -0.30555555 |
| Fifty Two Week Low | 14.72 |
| Fifty Two Week Low Change | 5.5299997 |
| Fifty Two Week Low Change Percent | 0.3756793 |
| Fifty Two Week Range | 14.72 - 29.16 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,767,969,000,000 |
| Float Shares | 26,390,974 |
| Forward Eps | -1.66333 |
| Forward P E | -12.174374 |
| Free Cashflow | -36,244,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -60,954,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.122770004 |
| Held Percent Institutions | 0.42238 |
| Implied Shares Outstanding | 55,276,002 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-01-09 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts. |
| Long Name | Aktis Oncology, Inc. |
| Market | us_market |
| Market Cap | 1,119,339,008 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_708181619 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -63,731,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,119,339,040 |
| Number Of Analyst Opinions | 4 |
| Open | 19.0 |
| Operating Cashflow | -64,127,000 |
| Operating Margins | -9.29144 |
| Payout Ratio | 0.0 |
| Phone | 617-461-4023 |
| Post Market Change | 0.049999237 |
| Post Market Change Percent | 0.24690981 |
| Post Market Price | 20.3 |
| Post Market Time | 1,776,469,943 |
| Previous Close | 18.6 |
| Price Eps Current Year | -16.418962 |
| Price Hint | 2 |
| Price To Book | -0.12681614 |
| Price To Sales Trailing12 Months | 172.28552 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.296 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.65 |
| Regular Market Change Percent | 8.87097 |
| Regular Market Day High | 20.4 |
| Regular Market Day Low | 18.795 |
| Regular Market Day Range | 18.795 - 20.4 |
| Regular Market Open | 19.0 |
| Regular Market Previous Close | 18.6 |
| Regular Market Price | 20.25 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 205,250 |
| Return On Assets | -0.15794 |
| Return On Equity | -0.29446 |
| Revenue Growth | 1.004 |
| Revenue Per Share | 7.986 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 53,403,173 |
| Shares Percent Shares Out | 0.042 |
| Shares Short | 2,320,091 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,000,396 |
| Short Name | Aktis Oncology, Inc. |
| Short Percent Of Float | 0.1466 |
| Short Ratio | 4.48 |
| Source Interval | 15 |
| State | MA |
| Symbol | AKTS |
| Target High Price | 34.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 32.5 |
| Target Median Price | 33.0 |
| Total Cash | 226,787,008 |
| Total Cash Per Share | 4.103 |
| Total Debt | 11,548,000 |
| Total Revenue | 6,497,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 19.095589 |
| Two Hundred Day Average Change | 1.1544113 |
| Two Hundred Day Average Change Percent | 0.060454346 |
| Type Disp | Equity |
| Volume | 205,250 |
| Website | https://www.aktisoncology.com |
| Zip | 2,210 |